US Bancorp
ABUS icon

US Bancorp’s Arbutus Biopharma ABUS Stock Holding History

US Bancorp’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.17K Sell
1,494
-94
-6% -$413 ﹤0.01% 3558
2026
Q1 		$7.15K Buy
1,588
+137
+9% +$599 ﹤0.01% 3470
2025
Q4 		$6.98K Hold
1,451
– – ﹤0.01% 3438
2025
Q3 		$6.59K Sell
1,451
-44
-3% -$162 ﹤0.01% 3451
2025
Q2 		$4.62K Buy
1,495
+44
+3% +$146 ﹤0.01% 3665
2025
Q1 		$5.06K Sell
1,451
-294
-17% -$980 ﹤0.01% 3655
2024
Q4 		$5.71K Sell
1,745
-468
-21% -$1.72K ﹤0.01% 3612
2024
Q3 		$8.52K Sell
2,213
-855
-28% -$3.28K ﹤0.01% 3415
2024
Q2 		$9.48K Buy
3,068
+1,617
+111% +$4.85K ﹤0.01% 3326
2024
Q1 		$3.74K Buy
+1,451
New +$3.76K ﹤0.01% 3594
2023
Q4 		– Sell
-1,909
Closed -$3.88K – 3967
2023
Q3 		$3.88K Hold
1,909
– – ﹤0.01% 3506
2023
Q2 		$4.39K Buy
+1,909
New +$4.97K ﹤0.01% 3512
2022
Q1 		– Sell
-475
Closed -$2K – 4048
2021
Q4 		$2K Buy
+475
New +$1.84K ﹤0.01% 3860
2017
Q3 		– Sell
-200
Closed -$1K – 3558
2017
Q2 		$1K Hold
200
– – ﹤0.01% 3442
2017
Q1 		$1K Hold
200
– – ﹤0.01% 3445
2016
Q4 		$0 Sell
200
-50
-20% -$145 ﹤0.01% 3527
2016
Q3 		$1K Hold
250
– – ﹤0.01% 3421
2016
Q2 		$1K Sell
250
-50
-17% -$212 ﹤0.01% 3455
2016
Q1 		$1K Hold
300
– – ﹤0.01% 3425
2015
Q4 		$1K Hold
300
– – ﹤0.01% 3501
2015
Q3 		$2K Hold
300
– – ﹤0.01% 3412
2015
Q2 		$4K Buy
300
+100
+50% +$1.52K ﹤0.01% 3320
2015
Q1 		$3K Hold
200
– – ﹤0.01% 3372
2014
Q4 		$3K Buy
+200
New +$3.45K ﹤0.01% 3360

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

US Bancorp's ABUS Position: Q2 2026 in Review

US Bancorp reduced its Arbutus Biopharma (ABUS) stake by 5.9% in Q2 2026, selling an estimated $413 and leaving 1,494 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3558.

US Bancorp first reported a position in ABUS in Q4 2014 and has held it in 24 quarters since. The position peaked at $9.48K in Q2 2024. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • US Bancorp held 1,494 shares of Arbutus Biopharma worth $7.17K as of Q2 2026.
  • US Bancorp sold 94 Arbutus Biopharma shares in Q2 2026, an estimated $413.
  • Arbutus Biopharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3558 holding.
  • US Bancorp first reported a position in Arbutus Biopharma in Q4 2014 and has held it in 24 quarters since.
  • US Bancorp's Arbutus Biopharma position peaked at $9.48K in Q2 2024.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.